Reaction
Atypical Haemolytic Uraemic Syndrome reporting signals
As of the last recalculation, Atypical Haemolytic Uraemic Syndrome appears in 796 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 114.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 184 | 114.9 | 115.3 |
| Ravulizumab | 40 | 81.4 | 81.7 |
| Basiliximab | 30 | 69.3 | 69.5 |
| Tacrolimus Ointment 0.1% | 192 | 52.8 | 52.9 |
| Tacrolimus Extended-Release Capsules | 192 | 52.7 | 52.8 |
| Carfilzomib | 53 | 52.4 | 52.5 |
| Tacrolimus | 202 | 44.9 | 44.9 |
| Sirolimus | 17 | 33.7 | 33.7 |
| Mycophenolate Mofetil | 137 | 31.7 | 31.7 |
| Mycophenolate Mofetil Hydrochloride | 137 | 31.6 | 31.6 |
| Gemcitabine Hydrochloride | 55 | 29.0 | 29.1 |
| Gemcitabine | 41 | 28.6 | 28.7 |
| Mycophenilic Acid | 21 | 27.2 | 27.2 |
| Mycophenolic Acid | 24 | 20.2 | 20.2 |
| Labetalol | 10 | 19.9 | 19.9 |
| Nebivolol | 11 | 18.3 | 18.3 |
| Daratumumab | 27 | 18.3 | 18.3 |
| Pegaspargase | 8 | 17.2 | 17.3 |
| Busulfan | 9 | 15.1 | 15.1 |
| Cisplatin | 37 | 12.9 | 12.9 |
| Bleomycin Sulfate | 5 | 12.7 | 12.7 |
| Thiotepa | 4 | 11.0 | 11.0 |
| Guanfacine | 3 | 10.0 | 10.0 |